LONDON--(BUSINESS WIRE)--Jul 25, 2018--Technavio has announced their latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat pertussis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180725005708/en/
Technavio has published a new report on the drug development pipeline for pertussis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Pertussis: Market overview
Pertussis is a highly contagious respiratory disease and is also known as whooping cough. The Bordetella pertussis bacterium is the causing agent of pertussis. When infected by pertussis, patients suffer from uncontrollable, violent coughing, which often makes it difficult to breathe. After coughing, someone with pertussis often needs to take deep breaths, which results in a whooping sound. People of all ages can be affected by pertussis, but it can be very serious, even deadly, for infants aged less than 1 year. People with pertussis usually spread the disease to another person by coughing or sneezing, or when spending a lot of time near one another where they share the breathing space. Many babies with pertussis are infected by older siblings, parents, or caregivers, who are unaware that they have this disease.
According to a senior market research analyst at Technavio, “People who are infected with pertussis are most contagious up to 2 weeks after the cough begins. Antibiotics may shorten the amount of time someone is contagious. Vaccination in the appropriate age and time is the best treatment available for pertussis.”
Pertussis: Segmentation analysis
This drug pipeline analysis report segments the pertussis market based on therapies employed (monotherapy and combination therapy), RoA (intramuscular, intranasal, subcutaneous, epicutaneous, and intravenous), therapeutic modality (vaccine, antibody, and monoclonal antibody), targets (pertussis toxin, Th17, FHA, and PNAG), MoA (immunostimulant, anti-pertussis antibody formation, Th1 systemic immunity, and PNAG inhibitor), geographical segmentation (APAC, Americas, and EMEA) and recruitment status (active, not recruiting, completed, not yet recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on mechanism of action, around 69% of the molecules that are being investigated for the treatment of pertussis are immunostimulant.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180725005708/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/25/2018 01:48 PM/DISC: 07/25/2018 01:48 PM